Aethlon Medical (AEMD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Aug, 2026Executive summary
Annual Meeting scheduled for October 1, 2026, will be held virtually to maximize shareholder participation and convenience.
Proxy materials, including the Proxy Statement and Annual Report, are available online and by mail to all shareholders of record as of August 10, 2026.
Shareholders are encouraged to vote by proxy or online, with multiple voting methods available.
Voting matters and shareholder proposals
Ten proposals will be voted on, including director elections, auditor ratification, equity plan amendments, capital structure changes, and approvals for future financing and warrant transactions.
Board recommends voting “FOR” all proposals except Proposal 5, which is not explicitly recommended.
Proposals include increasing authorized common and preferred shares, amending the equity incentive plan, and authorizing future share issuances for financing and warrant inducements.
Shareholder proposals for the next annual meeting must be submitted by April 13, 2027, for inclusion.
Board of directors and corporate governance
Board consists of five members, four of whom are independent under Nasdaq rules.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined responsibilities and independent chairs.
Board meetings and committee attendance exceeded 75% for all directors in FY 2026.
Code of Business Conduct and Ethics applies to all directors, officers, and employees.
No family relationships or arrangements exist among directors or executive officers.
Latest events from Aethlon Medical
- Ongoing oncology trials show Hemopurifier reduces cancer-linked blood markers with strong safety.AEMD
Emerging Growth Conference - Final oncology cohort underway, lower net loss, and $4M financing extend runway 12+ months.AEMD
Q1 2027 - Hemopurifier shows early promise in oncology trials, with strong platform and financial position.AEMD
Emerging Growth Conference - Auditor's going concern warning and a new offering of stock and warrants highlight financial risk.AEMD
Registration filing - Best-efforts offering seeks $3.3M for R&D and trials amid financial and Nasdaq compliance risks.AEMD
Registration filing - Australian cancer trial advances to final cohort after positive safety review, with key data expected soon.AEMD
Emerging Growth Conference 91 - Promising device results for long COVID and oncology trials advance in Australia and India.AEMD
Emerging Growth Conference 83 - Hemopurifier® shows promise in clearing viruses and EVs, with global trials and robust IP protection.AEMD
Corporate presentation - Operating expenses dropped 24% as Hemopurifier trials advanced in Australia and cash position improved.AEMD
Q1 2025